DIM
HRTX icon

DLK Investment Management’s Heron Therapeutics HRTX Stock Holding History

DLK Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.6K Buy
17,890
+6,200
+53% +$4.97K 0.03% 86
2026
Q1 		$9.35K Hold
11,690
– – ﹤0.01% 91
2025
Q4 		$15.2K Sell
11,690
-10,500
-47% -$13K 0.01% 87
2025
Q3 		$28K Buy
22,190
+4,800
+28% +$7.61K 0.01% 85
2025
Q2 		$36K Hold
17,390
– – 0.01% 82
2025
Q1 		$38.3K Hold
17,390
– – 0.02% 76
2024
Q4 		$26.6K Sell
17,390
-500
-3% -$810 0.01% 84
2024
Q3 		$35.6K Hold
17,890
– – 0.01% 102
2024
Q2 		$62.6K Hold
17,890
– – 0.03% 90
2024
Q1 		$49.6K Hold
17,890
– – 0.02% 92
2023
Q4 		$30.4K Buy
+17,890
New +$19.7K 0.01% 96

Other funds holding HRTX

CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
AR
Apeiron RIA Dallas, Texas $390M AUM 22.97% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
TWM
TopTier Wealth Management Muskego, Wisconsin $166M AUM
JWCA
J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

DLK Investment Management's HRTX Position: Q2 2026 in Review

DLK Investment Management increased its Heron Therapeutics (HRTX) stake by 53% in Q2 2026, buying an estimated $4.97K and bringing the position to 17,890 shares worth $62.6K. The position accounts for 0.03% of the portfolio, ranked #86.

DLK Investment Management first reported a position in HRTX in Q4 2023 and has held it in 11 quarters since. 17 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • DLK Investment Management held 17,890 shares of Heron Therapeutics worth $62.6K as of Q2 2026.
  • DLK Investment Management bought 6,200 Heron Therapeutics shares in Q2 2026, an estimated $4.97K.
  • Heron Therapeutics made up 0.03% of DLK Investment Management's portfolio in Q2 2026, its #86 holding.
  • DLK Investment Management first reported a position in Heron Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 17 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on DLK Investment Management's 13F filing for Q2 2026, filed 14 Jul 2026.